About Aveo

Science. Passion. Impact.

 

AVEO Pharmaceuticals integrates a proprietary cancer biology platform with drug development and commercial expertise in its efforts to discover and develop targeted cancer therapeutics. Driven by our commitment to cutting-edge science, and the passion of the AVEO team to develop novel cancer treatments that positively impact patients’ lives, AVEO is moving toward realizing its vision of becoming a fully integrated cancer therapeutics company.

 

The company's lead product candidate, tivozanib, is an oral, triple vascular endothelial growth factor (VEGF) receptor inhibitor. Tivozanib is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1, comparing tivozanib to sorafenib in patients with advanced kidney cancer, as well as in a series of clinical trials evaluating tivozanib in combination with other agents in multiple solid tumor settings.

 

In addition to tivozanib, AVEO has identified a collection of monoclonal antibodies using its Human Response Platform™ (HRP), a library of proprietary mouse models engineered to contain signature genetic mutations that are uniquely present in human disease. AVEO is not only using its capabilities to develop its own pipeline of oncology therapeutic candidates, but has also engaged in partnerships with leading biotechnology companies to leverage its platform. Thus far, the platform has produced a promising portfolio of monoclonal antibodies against novel targets including: hepatocyte growth factor (HGF), ErbB3 (a member of the epidermal growth factor receptor (EGFR) family), the receptor tyrosine kinase RON, the Notch family of receptors, and fibroblast growth factor receptor (FGFR).

 

AVEO’s most advanced antibody candidate, AV-299, binds to HGF. In collaboration with Merck, AVEO is evaluating AV-299 in a Phase 2 clinical trial in combination with gefitinib (Iressa™) for the treatment of non-small-cell lung cancer (NSCLC). AV-203 is a preclinical antibody candidate being developed in partnership with Biogen Idec that targets ErbB3 (HER3), a receptor that is typically over-expressed in many human cancers and has been implicated in the mechanism of resistance to radiotherapy and other drugs. AVEO is currently seeking to partner its preclinical programs in RON, Notch and FGFR.

 

AVEO is headquartered in Cambridge, Massachusetts. Shares of AVEO’s common stock trade on the NASDAQ under the symbol:  AVEO.